

**FOR IMMEDIATE RELEASE**

January 30, 2015

Listed Company Name: Eisai Co., Ltd.
 Representative: Haruo Naito
 Representative Corporate Officer and CEO
 Securities Code: 4523
 Stock Exchange Listings: First Section of the Tokyo Stock Exchange
 Inquiries: Sayoko Sasaki
 Vice President, Corporate Affairs
 Phone +81-3-3817-5120

**Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS)
 for the Fiscal Year Ending March 31, 2015**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 2015 (April 1, 2014 to March 31, 2015) previously announced on May 13, 2014, as follows:

1. Revised full-year consolidated financial results forecasts for the fiscal year ending March 31, 2015
 (April 1, 2014 to March 31, 2015)

(Unit: Millions of yen, unless otherwise noted.)

	Revenue	Operating profit	Profit before income taxes	Profit for the period	Basic earnings per share
Previously announced forecast (A) (May 13, 2014)	566,000	53,000	49,500	35,000	122.37 yen
Currently revised forecast (B)	555,000	30,000	27,000	35,000	121.97 yen
Change in amount (B - A)	-11,000	-23,000	-22,500	—	
Percentage of change (%)	-1.9%	-43.4%	-45.5%	—	
(Reference) Business results for the fiscal year ended March 31, 2014	599,490	66,398	62,298	38,501	134.13 yen

2. Reason for revision of the consolidated financial results forecasts

Revenue is forecasted to be ¥555,000 million (down ¥11,000 million from the previous forecast) due to factors such as greater than expected generic erosion within Japan and the slow growth of new products in the United States. Revenue for major products is forecasted to be ¥57,000 million for Pariet®/AcipHex® (up ¥4,000 million from the previous forecast), ¥68,500 million for Aricept® (down ¥7,000 million from the previous forecast), ¥36,500 million for Halaven® (down ¥2,500 million from the previous forecast) and ¥5,000 million for Fycompa® (down ¥4,500 million from the previous forecast).

Operating profit is forecasted to be ¥30,000 million (down ¥23,000 million from the previous forecast) due to factors such as a decline in gross profit, proactive expenditure aimed at returning to a growth trajectory from fiscal 2015 onward as well as the influence of exchange rates.

Regarding profit for the period, a decrease in tax expenses is expected due to the repayment of paid-in capital of a U.S. subsidiary of the Group. On the other hand, an increase in tax expenses is also expected due to a decrease in deferred tax assets brought about by changes in the corporate tax rate. As a result, a net reduction in tax expenses of approximately ¥20,000 million is being expected and therefore profit for the period is forecasted to be ¥35,000 million, unchanged from previous forecasts. Furthermore, the forecast for the total dividend for the year remains unchanged at ¥150 per share (same amount as the previous fiscal year).
